-
Mashup Score: 5Choose Your Affiliation - NYU Health Sciences Library - 28 day(s) ago
Users with access to atnyulmc.org should login with their NYU Langone Credentials. Users with access to home.nyu.edu should login with their NYU Credentials. Still have questions? See our
Source: library.med.nyu.eduCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 50
Despite the availability of multiple classes of lipoprotein-lowering medications, some high-risk patients have persistent hypercholesterolemia and may require nonpharmacologic therapy. Lipoprotein apheresis (LA) is a valuable but underused adjunctive therapeutic option for low-density lipoprotein cholesterol and lipoprotein(a) lowering, particularly in children and adults with familial hypercholesterolemia. In addition to lipid lowering, LA reduces serum levels of proinflammatory and prothrombotic factors, reduces blood viscosity, increases microvascular myocardial perfusion, and may provide beneficial effects on endothelial function. Multiple observational studies demonstrate strong evidence for improved cardiovascular outcomes with LA; however, use in the United States is limited to a fraction of its Food and Drug Administration–approved indications. In addition, there are limited data regarding LA benefit for refractory focal segmental glomerulosclerosis. In this scientific statemen
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 6
This special series of Diabetes Core Update is supported by an independent educational grant from Amarin Corp. For more than 30 years, statins have been the cornerstone of lipid management to reduce the risk of cardiovascular disease (CVD) and heart-related events. These medications have been proven to effectively lower LDL cholesterol levels and CVD risk in a wide array of patient populations. But even after patients meet their LDL cholesterol goals, the risk for CVD-related events isn’t completely
Source: diabetesjournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3Diabetes Core Update - Special Edition - Lipids Beyound Statins and LDL - Diabetes Core Update - Podcast en iVoox - 2 month(s) ago
In this special episode titled “Lipids – Beyond Statins and LDL Cholesterol”, our host, Dr. Neil Skolnik will discuss with two expert guests the details of treatment for LDL-Cholesterol, Triglycerides, and other lipid risk markers. This special episode is supported by an independent educational grant from Amarin. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health James Underberg, M.D. , Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease, Director of the Bellevue Hospital Lipid Clinic, and Past President of the National Lipid Association. Layla A. Abushamat, M.D., MPH, Assistant Professor, Department of Medicine in the Division of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas Selected references referred to
Source: www.ivoox.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 61Choose Your Affiliation - NYU Health Sciences Library - 6 month(s) ago
Users with access to atnyulmc.org should login with their NYU Langone Credentials. Users with access to home.nyu.edu should login with their NYU Credentials. Still have questions? See our
Source: library.med.nyu.eduCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
Though the reasons aren’t clear, drops in estrogen likely play a significant role in accelerating plaque, says Matthew Budoff.
Source: www.tctmd.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 15
New indications supported by CLEAR Outcomes trial
Source: www.medpagetoday.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 76Effect of Statin Use on Liver Enzymes and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) - 8 month(s) ago
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease with the prevalence of approximately 30%.1 The prevalence goes up among specific high-risk populations: 30-50% in patients with type 2 diabetes, and 80-90% in patients with obesity.2,3
Source: www.lipidjournal.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 8Wegovy Approved for Major Heart Disease Prevention - 8 month(s) ago
New indication for patients with obesity or overweight and a history of cardiovascular disease
Source: www.medpagetoday.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 8Wegovy Approved for Major Heart Disease Prevention - 8 month(s) ago
New indication for patients with obesity or overweight and a history of cardiovascular disease
Source: www.medpagetoday.comCategories: General Medicine News, CardiologistsTweet
#Psoriasis and #ASCVD Atherosclerotic CV Disease—Risk Factor or Risk Marker? Wonderful Editorial from @garshick @NYUCVDPrevent @JAMACardio https://t.co/gTEdN96qL7